In a press release – in English but with numerous grammatical errors – James Teague, Country President, AstraZeneca (Thailand) Ltd said:
"We have seen a series of significant and promising progress [sic] in AstraZeneca’s Covid-19 vaccine development in Thailand during the past weeks. First, the Thai Food and Drug Administration approved Siam Bioscience as a manufacturing facility for COVID-19 vaccine AstraZeneca. Last week, the samples of COVID-19 vaccine AstraZeneca made by Siam Bioscience passed the full tests the standard set [sic] by the Department of Medicial Sciences (DMS) for requirements such as chemical composition and safety.
"And today, I am happy to be able to inform you that the samples from the test batches of the Covid-19 vaccine made by Siam Bioscience had passed the quality testing at AstraZeneca’s designated laboratories in Europe and in the U.S.
"These significant progresses [sic] mean that we are getting closer to deliver the first batch of the vaccine to the government of Thailand."
According to the release, numerous safety tests and quality control measures are carried out at each step of manufacturing and distribution. This includes completing all steps in the quality assurance process, with each batch of vaccine undergoing more than 60 different quality control tests during its journey from manufacture to vaccination. To ensure consistent quality across supply chains, the release said, AstraZeneca has built an extensive, global analytical network.
Mr Teague continued: “Our focus is on delivering vaccines as quickly as possible whilst ensuring adherence to the highest safety and quality standards and processes. We will continue to work closely with the government to achieve that. We are well aware that increasing concerns and question [sic] have been raised around vaccine safety and the availability of supply to help Thais and the people in Southeast Asia to fight this terrible COVID-19 pandemic.
"I want to once again reiterate AstraZeneca’s commitment that we are putting science and the interest of society at the heart of our work. And we will remain true to our values by continuing to work with governments and other organisations towards broad and equitable access to the vaccine in a timely manner and at no profit during the pandemic.”